دورية أكاديمية
أعرض في EDS

The Prognostic Significance of Pretreatment White Blood Cell and Platelet Counts for Survival Outcome in Primary Lung Cancer.

التفاصيل البيبلوغرافية
العنوان: The Prognostic Significance of Pretreatment White Blood Cell and Platelet Counts for Survival Outcome in Primary Lung Cancer.
المؤلفون: Kha VV; Director Board, Can Tho Oncology Hospital, Can Tho, Vietnam., Ly TH; Department of Pathophysiology - Immunity, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.; Department of General Planning, Can Tho Oncology Hospital, Can Tho, Vietnam., Duy PDT; Department of Radiology, Can Tho Oncology Hospital, Can Tho, Vietnam., Hoa PT; Department of of Intenal Medicine, Can Tho Oncology Hospital, Can Tho, Vietnam., Cong BT; Department of Nuclear Medicine, Hanoi Medical University, Hanoi, Vietnam.; Center of Nuclear Medicine and Oncology, Hanoi, Vietnam.
المصدر: Materia socio-medica [Mater Sociomed] 2024; Vol. 36 (1), pp. 97-102.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Academy of Medical Sciences of Bosnia & Herzegovina Country of Publication: Bosnia and Herzegovina NLM ID: 101281595 Publication Model: Print Cited Medium: Print ISSN: 1512-7680 (Print) Linking ISSN: 15127680 NLM ISO Abbreviation: Mater Sociomed Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Sarajevo, Bosnia and Herzegovina : Academy of Medical Sciences of Bosnia & Herzegovina
Original Publication: Sarajevo : Udruženje za socijalnu medicinu-javno zdravstvo BiH
مستخلص: Background: In Vietnam, lung cancer ranks second among common types of cancer. Although there have been many advances in the diagnosis and treatment of lung cancer, it is still one of the deadliest types of cancer.
Objective: We investigated the prognostic value of pretreatment white blood cell (WBC) and platelet counts of patients with lung cancer.
Methods: This was a prospective, descriptive study with longitudinal follow-up. Data from 203 patients with stage IIIA-IV lung cancer presenting at Can Tho City Oncology Hospital between June 2020 and June 2022 were analyzed. Complete blood cell counts were obtained using standard methods. Lung cancer diagnoses and histological classifications were obtained from cancer registries. The optimal overall survival cutoff point for pretreatment WBC and platelet counts was determined using maximally selected rank statistics.
Results: The median follow-up was 6 (interquartile range 4-8) months and the median age was 61.3 years. The number of male patients was higher than the number of female patients. Most (71.4%) patients had adenocarcinoma; 62.1% of the patients had a WBC count of > 10 × 109/L and 38.4% had a platelet count of > 400 × 109/L. The median overall survival (OS) of all patients was 8 months. The 3-month, 6-month, and 1-year OS was 88.7%, 62.4%, and 28.3%, respectively. Patients with a WBC count of <9.18 × 109/L had a higher OS than those with a count of ≥ 9.18 × 109/L (17 months versus 8 months; p < 0.001) Patients with a platelet count of < 453 × 109/L had a higher OS than those with a count of ≥ 453 × 109/L (8 months versus 7 months; p < 0.001).
Conclusion: White blood cell and platelet count tests are routine investigations that are valuable, in combination with other factors, for predicting OS of lung cancer patients. They can help clinicians to monitor treatment response and survival.
Competing Interests: There are no conflicts of interest.
(© 2024 Vo-Van Kha, Tran-Thi Huong Ly, Phan Duong Thanh Duy, Pham-Thi Thanh Hoa, Bui Tien Cong.)
References: Transl Cancer Res. 2021 Mar;10(3):1249-1260. (PMID: 35116452)
Zhongguo Fei Ai Za Zhi. 2016 Nov 20;19(11):725-730. (PMID: 27866514)
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55. (PMID: 21081700)
Clin Cancer Res. 1996 Mar;2(3):553-9. (PMID: 9816203)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Br J Haematol. 1993 Mar;83(3):433-41. (PMID: 8485049)
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30. (PMID: 9689079)
J Thorac Dis. 2012 Apr 1;4(2):212-3. (PMID: 22833829)
Cytokine. 2008 Jun;42(3):277-88. (PMID: 18400509)
J Thorac Oncol. 2015 Sep;10(9):1243-1260. (PMID: 26291008)
Br J Haematol. 1991 Oct;79(2):286-90. (PMID: 1958487)
Oncol Rep. 2011 Jun;25(6):1541-4. (PMID: 21431281)
Oncologist. 2018 Jul;23(7):844-848. (PMID: 29650687)
J Clin Oncol. 1995 May;13(5):1215-20. (PMID: 7738624)
Mil Med. 2020 Dec 30;185(11-12):e2044-e2048. (PMID: 32857164)
Eur Respir J. 1996 Sep;9(9):1826-30. (PMID: 8880098)
Cancer Cell. 2011 Nov 15;20(5):576-90. (PMID: 22094253)
Platelets. 2021 Oct 3;32(7):919-927. (PMID: 32892682)
Respiration. 2004 Mar-Apr;71(2):170-3. (PMID: 15031573)
Blood. 2005 Jan 1;105(1):178-85. (PMID: 15367435)
Blood. 2014 Jul 10;124(2):184-7. (PMID: 24868077)
Cancer. 2001 Nov 1;92(9):2399-405. (PMID: 11745296)
BMC Pulm Med. 2020 Apr 20;20(1):96. (PMID: 32312252)
Blood. 1991 Oct 15;78(8):1969-74. (PMID: 1912578)
Front Oncol. 2019 Apr 26;9:295. (PMID: 31080780)
J Thorac Oncol. 2016 Jan;11(1):39-51. (PMID: 26762738)
Cancer Inform. 2019 Apr 05;18:1176935119837547. (PMID: 31057324)
Monaldi Arch Chest Dis. 2003 Jul-Sep;59(3):193-8. (PMID: 15065314)
Cancer. 2009 Sep 1;115(17):3919-23. (PMID: 19551882)
Transl Lung Cancer Res. 2016 Jun;5(3):288-300. (PMID: 27413711)
فهرسة مساهمة: Keywords: White blood cells; lung cancer; platelets
تواريخ الأحداث: Date Created: 20240409 Latest Revision: 20240410
رمز التحديث: 20240410
مُعرف محوري في PubMed: PMC10999138
DOI: 10.5455/msm.2024.36.97-102
PMID: 38590595
قاعدة البيانات: MEDLINE
الوصف
تدمد:1512-7680
DOI:10.5455/msm.2024.36.97-102